Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters.
CONCLUSION: AR is expressed in about one-third of TNBC and loss of AR immunoexpression does not predict adverse clinical outcomes. Larger cohorts for better characterisation of the role of AR immunoexpression in TNBC are warranted.
PMID: 31427547 [PubMed - in process]
Source: Malaysian Journal of Pathology - Category: Pathology Tags: Malays J Pathol Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Clear Cell Carcinoma | Genetics | HER2 | Malaysia Health | Pathology | Study